Professional
Added to YB: 2026-07-09
Pitch date: 2026-07-04
LLY [neutral]
Eli Lilly and Company
+0.65%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Market Cap
$1.1T
Pitch Price
$1.2K
Price Target
N/A
Dividend
0.56%
EV/EBITDA
31.28
P/E
43.89
EV/Sales
15.77
Sector
Pharmaceuticals
Category
growth
Show full summary:
Andrew Hill Investment Advisors Portfolio Holding: Eli Lilly and Company
LLY (holding update): Explosive rev growth from blockbuster diabetes/obesity GLP-1 treatments; reinvesting cash into global mfg capacity to fix supply shortages & expand pipeline. Emerging Alzheimer's franchise (Donanemab) plus oncology, immunology, CV bench. Well positioned for years.
Read full article (1 min)